CLINICAL APPLICATION OF
CAR T CELLS

NOVEMBER 16-17, 2017

Memorial Sloan Kettering Cancer Center
Zuckerman Research Center
417 East 68th Street
New York, NY 10065

www.mskcc.org/cartcell

Memorial Sloan Kettering
Cancer Center
CLINICAL APPLICATION OF CAR T CELLS

Chimeric antigen receptor (CAR) T-cell (‘Living Drug’) immunotherapy is showing promising results in the treatment of cancers. Over the years, MSK has accumulated a breadth of knowledge about developing and translating these clinical trials from bench to bedside.

MSK faculty, along with national and international experts, will discuss the clinical and translational aspects of cell therapies (CARs, TCRs, NKs), both for hematologic malignancies and solid tumors.

EDUCATIONAL OBJECTIVES
1. To learn new developments in CAR T-cell therapy
2. To learn patient toxicity management
3. To learn patient clinical trial management algorithms

MAIN SESSIONS
- CARs for B-cell Malignancies
- Managing Toxicities
- The Ins and Outs of Manufacturing Engineered Cells
- CARs for Non-B-cell Hematologic Malignancies
- Non-T-cell Therapies
- Novel Cell-based Technologies
- TCRs and BiTEs
- National Guidelines for CAR T-cell Therapy Programs
- CARs for Solid Tumors

BREAKOUT SESSIONS TOPICS
- Clinical and Operational Infrastructure of Engineered Cell Therapy
- Novel T-cell-based Technologies and Assays

TARGET AUDIENCE
The target audience includes medical oncologists and oncology fellows in training, basic scientists, research fellows in training, nurses, clinical trial research staff, immunologists, and surgeons with an interest in tumor immunology and immunotherapy.

POSTER PRESENTATIONS & NETWORKING RECEPTION
Participants are invited to join the course faculty for a networking reception at Rockefeller University’s Weiss Café on November 16th.

Rockefeller University
1230 York Avenue, New York, NY
5:00-7:00 PM

Join the conversation:
#MSKCART17

Memorial Sloan Kettering Cancer Center
MSK FACULTY (Continued)

David Scheinberg, MD, PhD  
Chair, Molecular Pharmacology Program  
Director, Experimental Therapeutics Center

Eric Smith, MD, PhD  
Assistant Attending  
Myeloma Service  
Division of Hematologic Oncology  
Department of Medicine

Craig B. Thompson, MD  
President and Chief Executive Officer

William Travis, MD  
Director, Thoracic Pathology  
Department of Pathology

Stephen Solomon, MD  
Chief Attending  
Interventional Radiology Service  
Department of Radiology

INVITED FACULTY (CME Session)

Joachim Aerts, MD, PhD  
Professor, Department of Pulmonary Disease  
Erasmus University Medical Center

Christopher Choi, PhD  
Member, Center for Immunotherapy  
Roswell Park Cancer Institute

Marco Davila, MD, PhD  
Associate Member  
Department of Blood and Marrow Transplantation  
Moffitt Cancer Center

Gianpietro Dotti, MD  
Professor, Department of Microbiology and Immunology  
University of North Carolina

Rong Fan, PhD  
Associate Professor  
Biomedical Engineering  
Yale University

Terry Fry, MD  
Head, Hematologic Malignancies Section  
National Cancer Institute

Saar Gill, MD, PhD  
Assistant Professor  
Department of Medicine  
Hospital of the University of Pennsylvania

Stephen Gottschalk, MD  
Chair, Department of Bone Marrow Transplantation and Cellular Therapy  
St. Jude Children’s Research Hospital

INVITED FACULTY (Non-CME Industry Session)

Yama Abassi, PhD  
Vice President, Global Strategic Business Development and Growth  
ACEA Biosciences

Adria Carbo, PhD  
Associate Director of Business Development  
Adaptive Biotechnologies

Elizabeth Faust, PhD  
Vice President, Medical Affairs  
Kite Pharma

Aaron Foster, MD  
Vice President, Product Discovery  
Bellicum Pharmaceuticals

Christopher Keir, MD, MS  
Vice President  
Global Head of Cell and Gene Medical Affairs  
Novartis Pharmaceuticals Corporation

Hyam Levitsky, MD  
Executive Vice President of Research and Chief Scientific Officer  
Juno Therapeutics

Julianne Smith, PhD  
Group Leader, Cellectis Therapeutics
DAY 1  
Thursday, November 16, 2017

8:00 AM  REGISTRATION & BREAKFAST

8:40 AM  Welcome & Introduction  
Prasad S. Adusumilli, MD

8:45 AM  Inaugural Remarks  
Craig B. Thompson, MD

SESSION I  
CARs for B-cell Malignancies

MODERATORS:  
Renier J. Brentjens, MD, PhD  
Terry Fry, MD

9:00 AM  Clinical Trials for B-cell ALL: the MSK Experience  
Jae Park, MD

9:15 AM  CD22 CAR T-cell Therapy  
Terry Fry, MD

9:30 AM  CD19 CAR T-cell Therapy for Relapsed and Refractory B-cell NHL  
Lia Palomba, MD

9:45 AM  Clinical Trials for B-cell NHL: the Moffitt Cancer Center Experience  
Frederick Locke, MD

10:00 AM  Discussion

10:15 AM  BREAK

SESSION II  
Managing Toxicities

MODERATORS:  
Marcela Maus, MD, PhD  
Craig Sauter, MD

10:30 AM  Neurotoxicity in CD19 CAR T-cell Clinical Trials  
Bianca Santomasso, MD, PhD

10:45 AM  CAR T-cell Toxicity Management Algorithms  
Marco Davila, MD, PhD

11:00 AM  ICU Management of CAR T-cell Patients: Evolving Paradigms  
Elena Mead, MD

11:15 AM  Discussion

SESSION III  
The Ins and Outs of Manufacturing Engineered Cells

MODERATORS:  
Isabelle Riviere, PhD  
Christopher Choi, PhD

11:30 AM  Evolution of CAR Manufacturing at MSK  
Isabelle Riviere, PhD

11:45 AM  Establishing a GMP Facility for Cell Therapies  
Christopher Choi, PhD

12:00 PM  LUNCH BREAK

SESSION IV  
CARs for Non-B-cell Hematologic Malignancies

MODERATORS:  
Katy Rezvani, MD, PhD  
Frederick Locke, MD

1:00 PM  IL18 Armored CARs  
Renier J. Brentjens, MD, PhD

1:15 PM  Combination of Ibrutinib and CD19 CARs for CLL  
Marcela Maus, MD, PhD

1:30 PM  BCMA-targeted CAR T-cell Therapy  
Eric Smith, MD, PhD

1:45 PM  Discussion

SESSION V  
Non-T-cell Therapies

MODERATORS:  
Gianpietro Dotti, MD  
Jae Park, MD

2:00 PM  CAR-directed NK Cell Therapy  
Katy Rezvani, MD, PhD

2:15 PM  Supercharged NK Cells for Cancer Therapy  
Anahid Jewett, MPH, PhD

2:30 PM  Dendritic Cell-based Immunotherapy for Solid Tumors  
Joachim Aerts, MD, PhD

2:45 PM  Discussion

3:00 PM  BREAK

SESSION VI  
Novel Cell-based Technologies

MODERATORS:  
Christopher Klebanoff, MD  
Rong Fan, PhD

3:15 PM  Single-cell Analysis in Cell Therapy  
Rong Fan, PhD

3:30 PM  Targeting a CAR to the TRAC Locus with CRISPR/Cas9  
Justin Eyquem, PhD

3:45 PM  Optional Non-CME Industry Sessions

5:00 PM  Poster Presentations & Networking Reception  
Weiss Café at Rockefeller University  
1230 York Avenue, New York, NY  
5:00-7:00 PM
**DAY 2**
**Friday, November 17, 2017**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Moderator/Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:15 AM</td>
<td>BREAKFAST</td>
<td></td>
</tr>
<tr>
<td>9:00 AM</td>
<td>Welcome Address</td>
<td></td>
</tr>
<tr>
<td>9:15 AM</td>
<td>Optional Non-CME Industry Sessions</td>
<td></td>
</tr>
</tbody>
</table>

**SESSION VII**
TCRs and BiTEs

**Moderators:**
- Stephen Gottschalk, MD
- David Scheinberg, MD, PhD

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Moderator/Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:45 AM</td>
<td>TCR Mimic Antibodies for Bispecific T-cell Engagers and CAR T cells</td>
<td>David Scheinberg, MD, PhD</td>
</tr>
<tr>
<td>11:00 AM</td>
<td>Adaptive Immunotherapy for Solid Cancers using TCR-engineered T-cell Subsets</td>
<td>Christopher Klebanoff, MD</td>
</tr>
</tbody>
</table>

**Keynote Speaker:**
- Next Generation of TCR-based Immunotherapies
  - Philip Greenberg, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Moderator/Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:45 AM</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>

**SESSION VIII**
Panel Discussion

**Moderators:**
- Paul Sabbatini, MD
- Prasad S. Adusumilli, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Moderator/Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00 PM</td>
<td>Rise of Immunotherapy in Oncology: How we are Incorporating it in our Departments</td>
<td>Philip Kantoff, MD, Jeffrey Drebin, MD, Andrew Kung, MD, William D. Travis, MD, Stephen Solomon, MD</td>
</tr>
</tbody>
</table>

**Keynote Speaker:**
- Next Generation of CAR-based Immunotherapies
  - Michel Sadelain, MD, PhD

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Moderator/Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00 PM</td>
<td>LUNCH BREAK</td>
<td></td>
</tr>
</tbody>
</table>

**SESSION IX**
National Guidelines for CAR T-cell Therapy Programs

**Moderators:**
- Kevin Curran, MD
- Helen Heslop, MD, DSc (Hon)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Moderator/Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:15 PM</td>
<td>Foundation for Accreditation of Cellular Therapy (FACT) Guidelines</td>
<td>Helen Heslop, MD, DSc (Hon)</td>
</tr>
<tr>
<td>2:30 PM</td>
<td>T-cell Collection, Production, and Delivery: Logistics &amp; Regulation</td>
<td>Sarah Nikiforow, MD, PhD</td>
</tr>
<tr>
<td>2:45 PM</td>
<td>CIBMTR Guidelines for Cellular Therapies</td>
<td>Miguel Perales, MD</td>
</tr>
<tr>
<td>2:55 PM</td>
<td>CAR T-cell Infusion/Follow-up: Logistics &amp; Regulation</td>
<td>Kevin J. Curran, MD</td>
</tr>
<tr>
<td>3:05 PM</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>3:15 PM</td>
<td>BREAK</td>
<td></td>
</tr>
</tbody>
</table>

**SESSION X**
CARs for Solid Tumors

**Moderators:**
- Roisin O’Cearbhaill, MD
- Saar Gill, MD, PhD

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Moderator/Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:30 PM</td>
<td>Dual Antigen-targeted CARs</td>
<td>Saar Gill, MD, PhD</td>
</tr>
<tr>
<td>3:45 PM</td>
<td>HER2-specific CARs for Solid Tumors</td>
<td>Stephen Gottschalk, MD</td>
</tr>
<tr>
<td>4:00 PM</td>
<td>Heparanase-expressing CAR T cells for Solid Tumor Therapy</td>
<td>Gianpietro Dotti, MD</td>
</tr>
<tr>
<td>4:15 PM</td>
<td>Mesothelin-targeted CARs</td>
<td>Edmund Moon, MD</td>
</tr>
<tr>
<td>4:30 PM</td>
<td>Combination Immunotherapeutic Approach for Solid Tumors</td>
<td>Prasad S. Adusumilli, MD</td>
</tr>
<tr>
<td>4:45 PM</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>4:55 PM</td>
<td>Concluding Remarks</td>
<td></td>
</tr>
</tbody>
</table>

**SYMPOSIUM ADJOURN**

#MSKCART17
REGISTRATION

<table>
<thead>
<tr>
<th></th>
<th>EARLY*</th>
<th>GENERAL</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Academia Fees</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physicians (MDs, PhDs, and DOs)</td>
<td>$500</td>
<td>$600</td>
</tr>
<tr>
<td>Residents, Fellows, Nurses, and Other Healthcare Providers</td>
<td>$200</td>
<td>$300</td>
</tr>
<tr>
<td><strong>Industry Fees</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All Members (any employee working for a commercial interest)</td>
<td>n/a</td>
<td>$1,500</td>
</tr>
</tbody>
</table>

*Early Registration Deadline 10/30/17

Register Online: www.mskcc.org/cartcell

REGISTRATION DETAILS
Registration includes continental breakfast, lunch, and refreshment breaks. Please contact cme@mskcc.org at least one week prior to the course if you have any special dietary needs.

- **30% Discounted Rate for MSK Alumni and MSK Alliance Members:** MSK offers a 30% discounted rate to all MSK Alumni and MSK Alliance members to attend a CME course. Please contact cme@mskcc.org for a promo code or more information.
- **MSK Staff Registration:** Registration is complimentary for MSK staff. However, you must register online at www.mskcc.org/cartcell.

**Industry Members** may attend CME activities for their own education. Marketing, sales, and promotion of products and services is strictly prohibited at MSK CME activities.

ACREDITATION STATEMENT
MSK is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA CREDIT DESIGNATION STATEMENT
MSK designates this live activity for a maximum of 10 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME hours from this conference qualify for the Federation for the Accreditation of Cellular Therapy (FACT) Immune Effector Cells (IEC) annual training requirement (10 hrs needed).

FACULTY DISCLOSURE
It is the policy of MSK to make every effort to insure balance, independence, objectivity, and scientific rigor in all continuing medical education activities which it provides as an ACCME accredited provider. In accordance with ACCME guidelines and standards, all faculty participating in an activity provided by MSK are expected to disclose any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services which are discussed by the faculty members in an educational presentation. As required by the ACCME, when an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, MSK requires the speaker to disclose that the product is not labeled for the use under discussion or that the product is still investigational.

CONFERENCE LOCATION
Memorial Sloan Kettering Cancer Center
Mortimer B. Zuckerman Research Center
417 East 68th Street
New York, NY 10065

ACCOMMODATIONS
MSK has negotiated special rates and amenities at select hotels in Manhattan. For information on hotels in the area of MSK with discounted rates, please visit: www.mskcc.org/cme.

CONTACT
For more information, including all upcoming MSK CME courses, visit our website at www.mskcc.org/cme. To contact us directly, email cme@mskcc.org.

Join the conversation:
#MSKCART17

/MSKCEME
@MSKCME
MSK CME LinkedIn Group